MGAT4B

Across TCGA pan-cancer cohorts, MGAT4B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MGAT4B data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MGAT4B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MGAT4B expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

LSCC, PDAC, and GBM are the cancer types where MGAT4B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.515	0.887	.011	13	view →
PDAC	DFS	Median	All	0.556	0.281	.007	10	view →
GBM	DFS	Median	All	0.731	0.406	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MGAT4B–LSCC (DFS)

Open the LSCC breakdown →